Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.
复制标题
预防严重急性呼吸综合征冠状病毒2型感染临床研制中的疫苗配方
DOI：
10.1016/j.addr.2020.12.006
复制
发表时间：
2021-03
影响因子：
16.1
通讯作者：
Ainslie KM
中科院分区：
文献类型：
--
作者：
Batty CJ;Heise MT;Bachelder EM;Ainslie KM
由严重急性呼吸道综合征冠状病毒2型（SARS-CoV-2）引起的COVID-19大流行导致了对有效和安全疫苗开发的前所未有的努力。在广泛的研究工作的帮助下，对先前的冠状病毒流行病进行了表征和制定对策，以及各种疫苗平台技术的最新发展，已经提出了数百种使用数十种运载工具和途径的候选疫苗，并在临床前进行了评估。高需求加上研究人员的巨大努力，导致至少31种候选疫苗在临床试验中取得了进展，其中许多疫苗使用的平台从未被批准用于人类。本综述将讨论成功预防SARS-CoV-2的疫苗的方法和要求，目前正在进行COVID-19预防临床试验的无数疫苗平台的背景，以及这些试验目前结果的总结。最后，对COVID-19疫苗开发中有待解决的配方问题以及可能值得进一步研究的抗原或佐剂进行了展望。
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented effort toward the development of an effective and safe vaccine. Aided by extensive research efforts into characterizing and developing countermeasures towards prior coronavirus epidemics, as well as recent developments of diverse vaccine platform technologies, hundreds of vaccine candidates using dozens of delivery vehicles and routes have been proposed and evaluated preclinically. A high demand coupled with massive effort from researchers has led to the advancement of at least 31 candidate vaccines in clinical trials, many using platforms that have never before been approved for use in humans. This review will address the approach and requirements for a successful vaccine against SARS-CoV-2, the background of the myriad of vaccine platforms currently in clinical trials for COVID-19 prevention, and a summary of the present results of those trials. It concludes with a perspective on formulation problems which remain to be addressed in COVID-19 vaccine development and antigens or adjuvants which may be worth further investigation.
登录
查看更多内容
影响因子：
64.8
作者：
Barnes CO;Jette CA;Abernathy ME;Dam KA;Esswein SR;Gristick HB;Malyutin AG;Sharaf NG;Huey-Tubman KE;Lee YE;Robbiani DF;Nussenzweig MC;West AP Jr;Bjorkman PJ
通讯作者：
Bjorkman PJ
影响因子：
5
作者：
Cameron MJ;Bermejo-Martin JF;Danesh A;Muller MP;Kelvin DJ
通讯作者：
Kelvin DJ
影响因子：
5.5
作者：
Beyer, WEP;Palache, AM;Osterhaus, ADME
通讯作者：
Osterhaus, ADME
影响因子：
4.7
作者：
Bale, Bradley Field;Doneen, Amy Lynn;Vigerust, David John
通讯作者：
Vigerust, David John
DOI：
10.1056/nejmoa1502924
发表时间：
2016-04-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Agnandji ST;Huttner A;Zinser ME;Njuguna P;Dahlke C;Fernandes JF;Yerly S;Dayer JA;Kraehling V;Kasonta R;Adegnika AA;Altfeld M;Auderset F;Bache EB;Biedenkopf N;Borregaard S;Brosnahan JS;Burrow R;Combescure C;Desmeules J;Eickmann M;Fehling SK;Finckh A;Goncalves AR;Grobusch MP;Hooper J;Jambrecina A;Kabwende AL;Kaya G;Kimani D;Lell B;Lemaître B;Lohse AW;Massinga-Loembe M;Matthey A;Mordmüller B;Nolting A;Ogwang C;Ramharter M;Schmidt-Chanasit J;Schmiedel S;Silvera P;Stahl FR;Staines HM;Strecker T;Stubbe HC;Tsofa B;Zaki S;Fast P;Moorthy V;Kaiser L;Krishna S;Becker S;Kieny MP;Bejon P;Kremsner PG;Addo MM;Siegrist CA
通讯作者：
Siegrist CA